Pregnenolone

Intro

Pregnenolone is a steroid hormone the body makes from cholesterol inside mitochondria, and it is the upstream precursor for every other steroid hormone — DHEA, progesterone, cortisol, aldosterone, testosterone, and estrogens all derive from it. The community calls it the mother hormone for this reason. Endogenous production peaks in the 20s and falls roughly 50-60% by age 60-75, which is the textbook rationale offered for supplementation. The compound itself was first studied in the 1940s for rheumatoid arthritis, autoimmune disease, and factory-worker fatigue. It worked in small trials but was abandoned in the early 1950s when cortisol, cortisone, and patentable synthetic glucocorticoids produced more dramatic anti-inflammatory effects and attracted all the pharma attention. Pregnenolone, unpatentable, sat unused for decades before community interest revived it. The modern revival came from two distinct tribes that mostly do not talk to each other. The bioenergetic community frames pregnenolone as essential for metabolic and thyroid function. The TRT community frames it as a backfill for neurosteroids suppressed by exogenous testosterone. Both groups converge on similar doses despite different mental models, which is one reason the compound is worth taking seriously. Mechanistically, the part most users actually feel is downstream. Pregnenolone itself binds Sigma-1, pregnane X, and CB1 receptors, and stabilizes microtubules, but it does NOT directly modulate GABA-A or NMDA receptors. The calming and clarity effects most users describe come from conversion to allopregnanolone (a strong GABA-A positive modulator) and to pregnenolone sulfate (a positive NMDA receptor modulator and cognitive enhancer). This split matters: supplementing pregnenolone gives the body a precursor it can route either way, which is why effects vary wildly between individuals depending on their downstream enzyme expression. The published clinical evidence is real but narrower than community claims suggest. Five randomized controlled trials at doses of 50-500 mg/day for 4-12 weeks show effects on bipolar depression, schizophrenia negative symptoms, chronic low-back pain in veterans, and alcohol craving. Pure cognitive endpoints in schizophrenia trials have failed, though functional capacity has improved. Safety has been consistent across trials at supraphysiologic doses, with no serious adverse signal exceeding placebo.

Observed Effects

Subjective effects most commonly reported. Calming effect, mental clarity, hydrated and improved skin, eye-strain relief, better sleep, reduced anxiety in social or pressured situations, and a milder emotional reactivity that users notice within hours of an evening dose. The 7-year self-experimenter at 75 mg/day described "focus, clarity, and staying calm under pressure... zero crash." A community first-day report at 10 mg with evening meal described a calming effect, clear-headedness, hydrated skin, and relief from prior eye irritation. Where the strongest single signal sits: testosterone tolerance on TRT. A long-running TRT community thread (191 replies) documents that 50-100 mg pregnenolone plus 25-50 mg DHEA daily lets men tolerate testosterone levels exceeding 1,500 ng/dL without the anxiety, tachycardia, insomnia, and overstimulation that high-dose T usually produces. The community theory is that exogenous testosterone suppresses LH and downstream Leydig cell pregnenolone production, leaving the user systemically short of a calming neurosteroid precursor while estrogenic and androgenic signals run hot. Backfilling the precursor restores the missing brake. Clinical trial outcomes. Five placebo-controlled randomized trials anchor the human evidence: - Bipolar depression (Brown et al. 2014, n=80, 500 mg/day, 12 weeks): 61% IDS-SR remission on pregnenolone vs 37% on placebo. The HRSD treatment-by-week interaction was significant (p=0.025). Anxiety improvement correlated negatively with rises in allopregnanolone and pregnanolone, supporting the downstream-conversion explanation. - Chronic low back pain in Iraq/Afghanistan veterans (Naylor et al. 2020, n=94, 100 → 300 → 500 mg titration over 4 weeks): significant reduction in daily pain ratings versus placebo over 6 weeks. Population was 89% male, mean age 37. - Schizophrenia negative symptoms (Ritsner et al. 2014, n=60, 50 mg/day, 8 weeks): PANSS negative symptom effect size d=0.79; specific improvement on blunted affect, avolition, and anhedonia at weeks 6-8 among patients not on mood stabilizers. - Schizophrenia proof-of-concept (Marx 2009, n=21, titrated to 500 mg/day, 8 weeks): SANS improvement 10.38 versus 2.33 placebo (p=0.048). Cognitive composites did NOT improve. Serum pregnenolone rises predicted cognitive outcomes only in baseline-deficient patients. - Schizophrenia in Singapore (n=120, titrated to 500 mg/day, 8 weeks): MATRICS cognitive composite did not change versus placebo. Functional capacity (UPSA-B) improved (p=0.03). Communication subscale improved markedly (p<0.001). Females showed a serum-pregnenolone-correlated response that males did not. - Alcohol use disorder (Milivojevic et al. 2023, n=43, 300 or 500 mg/day, 8 weeks): both doses reduced stress- and alcohol-cue-induced craving. 300 mg/day showed greater anxiety reduction than 500 mg/day — a non-monotonic, inverted-U dose response. Skin and aging. Bioenergetic-tradition users at 5-20 mg/day report visible skin improvement within days. Mechanism is plausible but not formally documented — likely some combination of cortisol modulation and mild estrogenic downstream conversion. What does NOT replicate. Pure cognitive enhancement endpoints fail consistently in schizophrenia trials. In healthy young adults with normal baseline levels, users often report no subjective effect at all (community threads from 19-year-olds on 50 mg note no positive or negative response). In rodents, pregnenolone is the most potent memory enhancer known. In humans, the rodent signal does NOT cleanly transfer for memory endpoints.

Field Reports

What works. The most consistent positive reports are emotional regulation — calm under social pressure, reduced reactivity, improved tolerance for stress and provocations.

Multiple users describe this as the most reliable subjective effect, far more than memory or libido. The 7-year self-experimenter at 75 mg/day captures it as "focus, clarity, and staying calm under pressure... zero crash." Skin improvement is the second-most-reported benefit, especially in lower-dose bioenergetic users. Sleep quality and reduced eye strain are common first-day reports. What doesn't work. Memory improvement, despite being the rodent-data headline, fails to materialize for most users. Younger users with normal baseline levels report no effect at all. Direct anabolic or hypertrophy effects are absent — pregnenolone supplementation does not build muscle, and bodybuilders chasing that effect are wasting money. Pure cognitive enhancement (working memory, processing speed) replicates poorly outside specific populations. Common mistakes. - Starting at 50-100 mg before testing tolerance. Bidirectional CNS response is the rule, not the exception. Starting at 5-10 mg is safer. - Using non-micronized or low-quality OTC product. Several users on standard OTC pregnenolone test at near-zero serum after months of supplementation. Trusted brands with micronized products make a measurable difference. - Morning dosing without good reason. Evening dosing aligns with the allopregnanolone-driven calm and sleep effect; morning dosing has been associated with first-day fatigue in several reports. - Assuming oral capsules deliver equivalent serum to sublingual or transdermal. Multiple TRT-community users have moved to sublingual after oral consistently failed to raise serum levels. - Stacking with stimulants on first trial. The downstream NMDA-positive modulation via pregnenolone sulfate is excitatory; stimulant stacks have produced insomnia and anxiety patterns. - Continuing despite paradoxical reactions. The 'ride it out' advice works for some users but not for those with genuine CNS sensitivity. If 5-10 mg produces sustained anxiety or insomnia over 2+ weeks, the compound is not for that user. How experienced users refine. Most experienced users settle on 25-50 mg evening, sublingual or micronized capsule, year-round dosing, paired with 25 mg morning DHEA. Bloodwork at 4-8 weeks confirms response; dose adjusts to bring serum pregnenolone into the 125-200 ng/dL range. Users who feel an effect at low dose typically do not push to higher doses — the inverted-U dose response in trials suggests more is not better for most goals. Reported product quality pattern. High-quality micronized capsules are the most-recommended oral form; sublingual preparations from TRT pharmacies are common when oral dosing fails to move serum. Topical forms are popular in bioenergetic circles but create more concern about prolonged tissue accumulation. Avoid generic warehouse-club or unbranded products — quality variability is real and documented. Self-test pattern. Many community users now follow a 30-day trial: start at 5-10 mg evening for 1 week, bump to 25 mg if tolerated, retest serum at 4 weeks. If no measurable serum response and no subjective effect, move to sublingual or change brand. If subjective benefit but flat serum, the subjective effect is likely placebo or downstream conversion not reflected in pregnenolone serum.

Community Consensus

Two distinct communities use pregnenolone heavily, with overlapping doses but very different mental models.

The TRT community. This is the largest user base. The framing is that exogenous testosterone suppresses LH, which reduces Leydig cell pregnenolone production and downstream neurosteroid availability. Symptoms that emerge during TRT — anxiety, insomnia, tachycardia, brain fog, irritability — are interpreted as neurosteroid depletion rather than testosterone excess. Pregnenolone (and DHEA) backfill is treated as standard practice, and experienced TRT educators are openly critical of clinics that ignore neurosteroid supplementation. The typical protocol is 25-100 mg evening pregnenolone with 25 mg morning DHEA, plus HCG, on top of testosterone replacement. The bioenergetic community. Smaller but vocal. Framing centers on metabolic and thyroid function. Pregnenolone is treated as a youth-associated steroid alongside DHEA and progesterone, and the protocols emphasize product quality over precise dosing. Topical preparations are more popular here. Effects emphasized are skin quality, calm under social provocation, and metabolic vitality. The post-finasteride syndrome (PFS) community. Distinct from both, with the most severe use cases. PFS users frame finasteride-induced 5-alpha reductase inhibition as causing a permanent allopregnanolone-deficit state that drives CNS symptoms (seizures in severe cases, jaw locking, cognitive impairment, sexual dysfunction). Pregnenolone is described as a slow 'bridge' rather than a cure; some users escalate to 400 mg/day for sustained periods. The most severe cases ultimately need IV allopregnanolone (brexanolone) which is cost-prohibitive at ~$30,000. Disagreement zones. Whether to use pregnenolone during AAS blast cycles divides the community — some pause it on the theory that supraphysiologic testosterone overwhelms the downstream cascade anyway, others continue it precisely because shutdown deepens neurosteroid depletion. Whether 'pregnenolone steal' is a real biochemical phenomenon or a heuristic for symptom-clustering is debated among practitioners. Whether oral pregnenolone is bioavailable enough to matter without sublingual or transdermal is a live argument — multiple users report near-zero serum despite OTC oral supplementation. Pushback on hype. Experienced TRT practitioners push back hard on the bodybuilding-marketing claim that pregnenolone boosts testosterone or supports hypertrophy. There are no quality human trials supporting hypertrophy use. Bodybuilders supplementing pregnenolone hoping for direct anabolic effects are operating on marketing copy. This pushback is community consensus among experienced TRT practitioners despite ongoing marketing in the bodybuilding supplement industry. Adoption history. Pregnenolone has been known since the 1930s and was clinically tested in the 1940s for arthritis, autoimmune disease, and fatigue. It worked but was abandoned when cortisol-based drugs proved more dramatic and patentable. The compound sat unused for decades and re-emerged through community channels in the 2010s, riding the modern TRT and bioenergetic revivals.

Risks & Monitoring

Pregnenolone's adverse profile is dominated by its bidirectional CNS effect: the same compound produces calm and clarity in some users and paradoxical anxiety, insomnia, or mania in others, often at the same dose.

Bridge-mechanism explains both directions — pregnenolone routes through Delta-4 (progesterone → allopregnanolone, calming via GABA-A) or Delta-5 (DHEA → androgens), and through sulfation to pregnenolone sulfate (positive NMDA modulation, stimulating). Individual conversion ratio drives whether a given user feels sedated, stimulated, or destabilized. Low-dose paradoxical reactions. A documented community user (5 mg total over 1 month for adrenal fatigue) developed strong dreams, light sleep, mid-night heart palpitations, two nights of strong insomnia, new sensitivity to loud sounds, throbbing pulse at multiple sites, body heat, and persistent anxiety. The user attributed it to permanent NMDA/GABA receptor adjustment. Another community user with above-range baseline pregnenolone took 5 mg and felt "weird and agitated." Both cases show that doses far below the community-typical range can cause significant CNS dysregulation in susceptible individuals — usually those with already-normal levels or coexisting CNS sensitivity. Delayed-onset adverse pattern on TRT. A repeatable pattern across multiple TRT users: 5 mg sublingual pregnenolone at night produces a good first-night sleep, then a 12-hour-delayed headache or depression-like crash the next day. The pattern reproduced "at least 10 different times" in one user. Some users describe this as transient and ride it out; others find it worsens with consecutive daily dosing. Catastrophic case in a polypharmacy context. A 26-year-old community user developed psychotic-spectrum dysfunction lasting months after a naturopath prescribed oral pregnenolone + DHEA following prior fluoroquinolone use. The case suggests downstream GABA-A/NMDA receptor sensitization or peripheral nervous system damage can be exacerbated by exogenous neurosteroid load. Rare, but documented; the population at risk is users with recent quinolone exposure or known GABA-receptor sensitivity. Skin reactions: bidirectional. Some users (bioenergetic community) report glowing skin and improved complexion within days at 5-20 mg/day. Others develop massive acne and skin rash from doses as low as 5 mg, lasting after discontinuation. The conversion ratio to downstream androgens versus progesterone-line neurosteroids likely drives the split. Persistent color-perception changes from topical pregnenolone. One TRT-community user reported enhanced color perception, especially flashing colors, that persisted more than a year after stopping topical pregnenolone cream. Hypothesized cause: lipophilic accumulation in subcutaneous fat with very slow release. Single case but consistent with topical steroid pharmacokinetics. Other reported reactions. Headache, fatigue, hair loss, diarrhea, restlessness, irritability, persistent mild depression-like feeling, and worsening of hyperthyroid symptoms (in a single Graves Disease user). Most reports describe these as dose-related and reversible within days of stopping. PFS-related cascade collapse. In severe post-finasteride syndrome users, pregnenolone can be part of a recovery protocol that nonetheless includes evening-onset seizures (10-15 in three weeks reported by one user), jaw locking, lower back pain, neck pain, and speech difficulty. The compound is described in this population as a slow "bridge" to allopregnanolone — useful but not equivalent to IV allopregnanolone (a postpartum medication costing ~$30,000), which reportedly reverses the same symptoms acutely. Pregnenolone alone is inadequate for acute decompensation in severe PFS. Clinical trial tolerability. Across all five major RCTs at doses up to 500 mg/day for 8-12 weeks, pregnenolone was "well tolerated" with no serious adverse events exceeding placebo. The community adverse spectrum above appears in a different population (chronically stacked TRT users, PFS patients, bioenergetic enthusiasts) and reflects real-world response variability that controlled trials may filter out.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Backfill on TRT. 25-100 mg pregnenolone in the evening, paired with 25 mg DHEA in the morning.

This is the dominant community use case. Target serum pregnenolone 125-200 ng/dL and DHEA-sulfate middle-to-top of reference range. If high-dose testosterone is causing anxiety, insomnia, or overstimulation, scale pregnenolone toward 50-100 mg. Some users add 250-500 IU HCG 2-3x weekly to support endogenous adrenal and testicular precursor production, which independently raises DHEA-sulfate. Post-finasteride syndrome (PFS) recovery. 100-400 mg/day in the evening, often paired with HCG and sometimes allopregnanolone or progesterone. This is the most extreme use case in the community and the dose range with the least clinical safety data. Severe PFS users describe pregnenolone as a slow 'bridge' rather than a cure — IV allopregnanolone has been described as faster but is cost-prohibitive (~$30,000). Physical and mental rest are critical alongside; exertion can trigger CNS decompensation. Mood and bipolar depression (adjunctive). Clinical-trial dose is 500 mg/day titrated from 50-100 mg over 1-2 weeks. Maintain for 12 weeks. Used as add-on to existing psychiatric medication, not standalone. Outside trial protocols, community users with depressive symptoms typically run 50-100 mg in the evening for a similar duration. Anxiety reduction. 300 mg/day was more effective than 500 mg/day in the Milivojevic alcohol-use trial. The community range of 25-100 mg evening also works for many users with milder anxiety, particularly in TRT contexts. Higher doses are not necessarily better for anxiety. Cognitive support. Evidence for direct cognitive enhancement is weak. If users want this benefit, they should accept that results are inconsistent and most likely benefit accrues to baseline-deficient older users. 25-50 mg evening is reasonable. Do not stack with stimulants on first trial — bidirectional CNS response is the rule. Women's protocols. Lower dose, cycle-aware: 25 mg pre-ovulation, up to 50 mg post-ovulation. Skin and mood benefits are commonly reported. Avoid during pregnancy. Track menstrual regularity — pregnenolone converts down both Delta-4 (progesterone-line) and Delta-5 (androgen-line); androgenic-side conversion at higher doses can cause acne and menstrual changes in some women. 5-alpha reductase inhibitor users. Men taking finasteride or dutasteride for hair loss often add 25-50 mg evening pregnenolone with the theory that 5AR inhibition cuts the conversion of progesterone to allopregnanolone, and pregnenolone supplementation rebuilds the upstream pool. This is community standard rather than RCT-supported; users should track mood and sexual function changes. Longevity and bioenergetic use. 5-20 mg/day, evening, often paired with DHEA, magnesium, and a thyroid-supportive protocol. Skin, energy, and mood are the reported outcomes. Bioenergetic users emphasize product quality and trusted brands more than dose.

Dosing Details

Starting dose. 5-10 mg in the evening with food. The community's most-burned-by-paradoxical-reactions users started at 5 mg, but this is exactly the dose that has produced both placebo-like responses and severe CNS reactions.

Starting low and adding slowly is the only sane approach. Community standard range. 25-100 mg/day for men and women, single evening dose. Practitioner consensus targets serum pregnenolone around 125-200 ng/dL. Most well-tolerated users settle into the 25-50 mg range; outliers go to 75-100 mg. Clinical trial range. 50-500 mg/day, morning escalation. RCT protocols typically titrated 100 mg week 1, 300 mg week 2, 500 mg weeks 3-4 (Naylor 2020 chronic low back pain). For mood disorders, 500 mg/day was the studied dose for 8-12 weeks (Brown 2014 bipolar, Marx 2009 schizophrenia). Lower clinical dose (50 mg/day for 8 weeks) replicated the negative-symptom signal in Ritsner 2014. Anxiety responded better to 300 mg/day than 500 mg/day in the Milivojevic 2023 alcohol use disorder trial — a non-monotonic dose response that argues against assuming more is better. Why community doses run lower than trial doses. Trial doses are pharmacologic — pushing serum and downstream neurosteroids far above physiologic. Community doses target restoration to youthful physiologic levels. Both approaches work for different purposes; do NOT confuse them. Timing. Single evening dose with last meal is standard. Allopregnanolone-driven calming effect aligns with sleep. Morning dosing has been associated with first-day fatigue in some users (30 mg morning report). Split dosing morning + evening is possible but not commonly used. Route. Oral micronized capsules are most common — Life Extension, Pure Encapsulations, Thorne, BalancedBodyMind are community-trusted brands. Bioavailability via oral first-pass is inconsistent — multiple users on standard OTC oral capsules test at near-zero serum despite stated dosing. Sublingual administration (capsule contents under tongue, or dedicated sublingual product) bypasses first-pass and produces more reliable absorption. Compounded transdermal cream is used by some practitioners (Dermacrine, Idealabs StressNon); reported as more consistent than oral capsules but lipophilic accumulation in fat tissue may extend the effective half-life unexpectedly. Cycle length and continuity. Most TRT-adjacent users dose pregnenolone continuously, year-round. Some pause during AAS blast cycles on the theory that exogenous testosterone overwhelms downstream cascade balance; others run pregnenolone year-round including blasts on the theory that suppressed neurosteroid production is precisely the gap to fill. Both patterns coexist. Titration cadence. Recheck serum pregnenolone and DHEA-sulfate at 4-8 weeks. Adjust dose to bring serum into target range (125-200 ng/dL pregnenolone, middle-to-top reference for DHEA-S). For users who feel an effect, dose may be increased gradually by 10-25 mg every 4 weeks if labs and subjective response support it. Reconstitution and storage. Capsules are stable at room temperature. Compounded cream should be refrigerated. Micronized form is preferred for absorption — non-micronized pregnenolone is poorly bioavailable. Stopping. No taper required for low-to-moderate doses. After supraphysiologic 300-500 mg doses, abrupt discontinuation has not produced clear withdrawal in trials, though serum levels return to baseline within days. Long-term users have reported subjective decline within 1-2 weeks of stopping.

Stacks & Alternatives

The community-default pairing. Pregnenolone is the upstream precursor, DHEA is the downstream androgen precursor; both are usually depleted on TRT or with age and most practitioners supplement both together. Typical: 25 mg DHEA morning + 25-50 mg pregnenolone evening.

Standard TRT-adjunct combination. HCG stimulates testicular and adrenal steroidogenesis, which independently raises endogenous DHEA-sulfate and pregnenolone. Together they form a 4-component 'backfill' stack with testosterone for full-spectrum hormone support.

The largest use case. Pregnenolone is added when TRT alone produces side effects — anxiety, tachycardia, insomnia — that suggest neurosteroid suppression. Community theory: exogenous testosterone reduces LH and downstream Leydig cell pregnenolone synthesis, and backfill restores the missing calming precursor.

Bioenergetic-tradition pairing. Magnesium supports GABA tone and NMDA modulation, complementing pregnenolone's downstream allopregnanolone effect. No formal evidence for synergy but very common community pattern.

In severe PFS or post-partum-style cascade collapse, direct allopregnanolone delivery (IV brexanolone) acts faster than oral pregnenolone bridge. Lower-cost alternative: oral or topical progesterone added to pregnenolone to feed the Delta-4 conversion path more directly.

Bioenergetic protocols pair pregnenolone with thyroid support. Theory: pregnenolone and thyroid both support adrenal and metabolic function. Empirical pairing, not RCT-supported.

For TRT users with Gilbert Syndrome who also use pregnenolone — supports bilirubin clearance against TRT-induced hematocrit elevation. Adjunct, not directly synergistic with pregnenolone effects.

Alternatives

Stack Cost

Practical Setup

access. Pregnenolone is legal over-the-counter as a dietary supplement in the United States; restricted in several other countries (Canada and Australia require prescription).

Trusted brands include Life Extension, Pure Encapsulations, Thorne, and BalancedBodyMind. Avoid generic or warehouse-club product — multiple community reports document zero serum response on questionable OTC product. For sublingual or topical formulations, TRT-friendly compounding pharmacies are the typical route. Forms. Several formulations have meaningfully different absorption profiles: - Oral micronized capsule — community standard, but inconsistent bioavailability. First-pass hepatic metabolism is substantial. Typical dose 10-100 mg. - Sublingual — capsule contents held under the tongue or dedicated sublingual product. Bypasses first-pass metabolism, more reliable serum response. Typical dose 5-50 mg. - Transdermal cream (Dermacrine, Idealabs StressNon, custom compounds) — also bypasses first-pass; produces steadier serum levels but lipophilic compound can accumulate in subcutaneous fat with prolonged use (one community user reported color-perception changes persisting >1 year after stopping topical pregnenolone cream). - Non-micronized oral — poorly bioavailable, avoid. - Indirect via HCG — HCG stimulates endogenous testicular and adrenal pregnenolone production. Not interchangeable with direct supplementation but used as a complement. Storage. Capsules at room temperature. Cream refrigerated. Sublingual liquids at room temperature. Standard pharmacy storage; nothing special. Drug interactions. Pregnenolone's downstream conversion to allopregnanolone has been shown to attenuate benzodiazepine-induced sedation in healthy adults (Meieran 2004 chronic-pregnenolone study). This is the only formally documented drug interaction. In practice, the bidirectional CNS effect can interact unpredictably with SSRIs, MAOIs, and recreational stimulants — start low and titrate cautiously if any of those are present. Signs to adjust dose down. Insomnia, paradoxical anxiety, headache, palpitations, mid-night waking, persistent depression-like crash 12 hours after dosing, acne, restlessness, hyperthyroid-like agitation. If any of these emerge at 25-50 mg, drop to 5-10 mg or stop entirely. Signs to adjust dose up. No subjective effect after 4 weeks at 25 mg, serum pregnenolone still below 125 ng/dL on testing, persistent symptoms of neurosteroid deficit (anxiety on TRT, brain fog, sleep disruption). Increase by 10-25 mg every 4 weeks until target serum or subjective response. Practical tips. - Take with the last meal of the day; the calm effect aligns with sleep. - If using sublingual, let capsule contents dissolve fully under tongue for 30-60 seconds before swallowing. - Track DHEA-sulfate alongside pregnenolone — both are typically low together, and DHEA-S is more reliably measured. - Do not assume oral and transdermal at the same labeled dose deliver equivalent serum. They do not. - Pregnenolone is unpatentable, which is why no pharma company is running large modern trials. Do not interpret the lack of phase-3 development as a quality signal. What is NOT a recommended panel cadence but is useful background. TRT users with Gilbert Syndrome should track bilirubin and CBC because TRT-driven hematocrit elevation worsens the underlying bilirubin clearance problem. Pregnenolone itself does not cause this; co-management matters because the populations overlap. Cost. $10-30/month at standard oral doses from quality brands. Compounded sublingual or cream runs $30-60/month. Far cheaper than HCG, far cheaper than the TRT it usually accompanies.

Mechanism Deep Dive

The biosynthetic foundation. Pregnenolone is synthesized from cholesterol inside mitochondria by the enzyme CYP11A1 (P450scc — side-chain cleavage enzyme).

This is the rate-limiting step of the entire steroidogenic cascade, and it depends on translocator protein (TSPO, 18 kDa) to shuttle cholesterol into the mitochondrial inner membrane. TSPO ligands are the only drug class shown to consistently raise endogenous pregnenolone (Lin et al. 2022). From pregnenolone, the body branches into two pathways: - Delta-5 pathway: Pregnenolone → 17α-hydroxypregnenolone → DHEA → Androstenedione → Testosterone → DHT or Estradiol. - Delta-4 pathway: Pregnenolone → Progesterone → 17α-hydroxyprogesterone → 11-deoxycortisol → Cortisol; separately, Progesterone → 5α-dihydroprogesterone → Allopregnanolone via 5-alpha reductase and 3α-hydroxysteroid dehydrogenase. The split between these pathways is dynamic and individual-specific. Chronic stress is community-shorthanded as "pregnenolone steal" — preferentially shunting toward cortisol at the expense of downstream sex hormones and allopregnanolone. Endocrinology disputes 'steal' as a literal mechanism (the cascade is more complex), but the clinical pattern of low DHEA/allopregnanolone alongside elevated cortisol is real. Pregnenolone itself versus pregnenolone sulfate. This distinction matters and is often missed. Unsulfated pregnenolone has minimal direct GABA-A or NMDA receptor modulatory activity (Kilstrup-Nielsen 2022). Its biological targets are: - Sigma-1 receptor — chaperone protein involved in stress response and neuroprotection. - Pregnane X receptor (PXR) — nuclear receptor involved in xenobiotic metabolism. - CB1 (cannabinoid type 1) receptor — allosteric modulation, potentially explaining mild anxiolytic effects. - Microtubule-associated proteins (MAP2, CLIP170) — pregnenolone stabilizes microtubules. This is the active drug-development target for CDKL5 deficiency disorder via the synthetic derivative pregnenolone methyl ether (Kilstrup-Nielsen 2022). Pregnenolone sulfate (PregS). This is the active CNS pharmacological agent that most of the literature is actually describing. PregS is generated by sulfotransferase enzymes and circulates as a longer-half-life reservoir form. Its direct activities: - Positive NMDA receptor modulation — high-potency (nanomolar) signaling through Ca2+ and GPCR-dependent NMDAR trafficking to the cell surface (Springer 2014 review). Drives long-term potentiation and memory formation. - Intracellular Ca2+ enhancement — EC50 ~2 pM, picomolar range. Unusual potency for a steroid. - TRP channel modulation — activates and modulates transient receptor potential ion channels (Harteneck 2013). Relevant to pain processing and sensory function. - Negative GABA-A modulation — opposite of allopregnanolone. This is why high-dose pregnenolone sulfate can produce stimulating or anxiogenic effects when allopregnanolone-side conversion is overwhelmed. Allopregnanolone. The downstream metabolite that most users actually want and feel. Generated from progesterone via 5-alpha reductase (5AR) and 3α-hydroxysteroid dehydrogenase. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors at a binding site distinct from benzodiazepines. It is anxiolytic, sedating, sleep-promoting, anticonvulsant, and emotionally regulating. IV allopregnanolone (brexanolone) is the FDA-approved postpartum depression medication. 5-alpha reductase inhibition (finasteride, dutasteride) breaks the allopregnanolone pathway. This is why post-finasteride syndrome involves cognitive, sexual, and mood symptoms beyond what DHT-removal alone explains: the same enzymatic step that produces DHT from testosterone also produces allopregnanolone from progesterone, and 5AR inhibitors block both. Why pregnenolone is the precursor of choice over direct allopregnanolone. Pregnenolone is cheap, oral, OTC. Allopregnanolone delivery options are limited to extremely expensive IV brexanolone or compounded oral progesterone (which still requires intact 5AR activity to convert). Pregnenolone gives the body discretion over how to route — partial conversion to allopregnanolone via Delta-4 plus simultaneous reservoir as pregnenolone sulfate. The trade-off is variable conversion efficiency — some users route mostly toward androgens, some toward allopregnanolone, some toward cortisol, and the subjective experience varies accordingly. TSPO and endogenous restoration. Translocator protein (TSPO) ligands raise endogenous pregnenolone synthesis without requiring exogenous supplementation. This is an active drug-development area for psychiatric and neurological indications. Until those drugs reach approval, exogenous oral or topical pregnenolone is the practical substitute. Neuroprotective and anticonvulsant mechanisms. Neurosteroids broadly demonstrate seizure modulation and neuroprotection via ionotropic receptor modulation in both genomic and non-genomic pathways (Borowicz et al. 2011). Pregnenolone specifically promotes neurogenesis, neuronal survival, and myelination at physiologic and pharmacologic concentrations (Mellon 2007). Why oral bioavailability is poor. Pregnenolone is a lipophilic steroid with substantial first-pass hepatic metabolism. Standard oral capsules deliver inconsistent serum response — explaining why many community users see near-zero pregnenolone serum despite stated dosing. Sublingual and transdermal routes bypass first-pass and produce more reliable absorption. Lipophilic accumulation in fat tissue with chronic transdermal use is a documented community-level concern. Why the rodent-to-human translation gaps for memory. Pregnenolone is the most potent known memory enhancer in rodents. In humans, this signal does NOT cleanly replicate. The likely reasons: longer human cognitive endpoints have higher placebo responses, human conversion ratios differ from rodents, and 17α-hydroxypregnenolone (an intermediate Delta-5 metabolite) exists in humans but not rodents — meaning the precursor flow is genuinely different across species.

Evidence Index